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Background
Vicriviroc (SCH 417690) inhibits HIV-1 infection by
blocking the viral CCR5 co-receptor. Early HIV replication
is associated with rapid depletion of CCR5+ CD4 T lym-
phocytes that predominate in gut-associated lymphoid
tissue (GALT), an important site of early establishment of
HIV infection. Given the rapid absorption of oral Vicrivi-
roc, appreciable drug exposure to GALT is predicted,
potentially protecting this important component of the
immune system.
Materials and methods
An oral 5 mg/125 µCi/kg dose of 14C-labeled Vicriviroc
was administered to rats and drug concentrations deter-
mined by autoradiographic techniques at various time-
points up to 168 hr.
Results
Vicriviroc rapidly permeated the gut wall resulting in
appreciable drug exposure to GALT. The rank-order in
cumulative Vicriviroc exposure was GALTl > ymph node ≥
lungs > blood, although exposure to GALT<spleen. GALT
drug concentrations up to 48 hr were 10- to 103-fold
higher than the targeted IC90 concentration (IC90 = 6
nM). Differences in cumulative drug exposure between
GALT and other tissues was the result of differences in
both the observed peak drug concentration and in clear-
ance rates from the individual tissues.
Conclusion
Results suggest that high and sustained Vicriviroc concen-
trations in GALT can be achieved by as little as a single
oral dose, which may prevent viral replication in these tis-
sues and reduce the depletion of CCR5+ CD4 T lym-
phocytes.
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